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eactive  oxygen  species  overload  promotes
poptosis in JAK2V617F-positive  cell  linesoão Agostinho Machado-Neto, Fabiola Traina ∗
niversidade de São Paulo (USP), Riberão Preto, SP, Brazil
snake venom exhibits cytotoxicity and induces apoptosis inhiladelphia chromosome-negative myeloproliferative neo-
lasms (MPNs), including essential thrombocythemia (ET),
olycythemia vera (PV) and primary myeloﬁbrosis (PMF),
re characterized by excessive myeloid proliferation, with
redominant megakaryocytic, erythroid, and megakary-
cytic/granulocytic expansion, respectively, and have a
otential of transformation to acute myeloid leukemia.1 From
he molecular point of view, the Janus kinase 2 (JAK2)/signal
ransducer and activator of transcription (STAT) signaling
athway plays an important role in the pathogenesis of MPNs.
 recurrent gain-of-function mutation, V617F in JAK2, has
een reported in most PV cases and in more  than half of
T and PMF  cases.2 In JAK2V617F-negative patients, other
ain-of-function mutations in genes related to JAK2/STAT
ignaling activation, including JAK2 exon 12,3 MPL4 and Cal-
eticulin mutations,5,6 have been identiﬁed.
The current therapies for MPN  are limited and do not
esult in the elimination of the malignant clone. The only
urative approach for these diseases is allogeneic stem cell
ransplantation.7 Ruxolitinib is a selective JAK1/2 inhibitor
pproved by the Food and Drug Administration (FDA) of the
nited States for the treatment of intermediate and high-risk
MF  and PV patients with inadequate response or intolerance
o hydroxyurea. Results from phase III clinical trials demon-
trated that ruxolitinib is well tolerated, reduces inﬂammatory
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pen  access article under the CC BY-NC-ND license (http://creativecomcytokines and splenomegaly, and ameliorates constitutional
symptoms in PMF patients.8–10 Similarity, ruxolitinib con-
trols the hematocrit levels, reduces the spleen volume, and
improves symptoms in PV patients.11 However, ruxolitinib
treatment does not reverse bone marrow ﬁbrosis, suggesting
that additional therapeutic strategies are required.
Reactive oxygen species (ROS) play a singular role in MPN
cell biology. Marty et al.12 showed that hematopoietic cells
from a JAK2V617F knock-in mice model present higher levels
of ROS compared to those from normal mice, contributing to
DNA damage and genomic instability, which promote disease
progression. An increased basal level of ROS was also observed
in primary hematopoietic cells from MPN patients compared
to those from healthy donors.13,14 Ahn et al.,14 exploring the
molecular mechanism of elevated JAK2V167F-induced ROS
levels and cell survival under this stress condition, found that,
due to DNA damage, B-cell lymphoma-extra large (BCL-XL)
repression may be compromised.
In the current edition of the Revista Brasileira de Hema-
tologia e Hemoterapia, Tavares et al.15 report that l-amino
acid oxidase (LAAO) derived from Calloselasma rhosostoma:123–34.
ade de Medicina da Universidade de São Paulo (USP), Av. Ban-
JAK2V617F-cell lines (HEL and SET2) in a ROS production-
dependent manner. The anti-cancer effects of the LAAO
isolated from the venom of other snake species has been
 e Terapia Celular. Published by Elsevier Editora Ltda. This is an
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Calloselasma rhodostoma venom. Int J Biol Macromol.180  rev bras hematol hem
described in solid tumors16–18 and leukemia19,20 cell lines.
Notably, it has been reported that LAAO isolated from C.
rhosostoma20 and Bothrops pirajai19 did not exert a promi-
nent cytotoxic effect in peripheral blood mononuclear cells
isolated from healthy donors and that rusvinoxidase, the
LAAO isolated from Daboia russelii russelii was non-toxic in
mice,21 suggesting that cancer cells may be more  suscepti-
ble to the cytotoxicity induced by these compounds. Recently,
Mukherjee et al.21 observed that treatment with rusvinoxi-
dase induces ROS production and caspases activation, and
also downregulates BCL-XL in the MCF-7 breast cancer cell
line.
The work by Tavares et al.15 is an important step to estab-
lishing the cellular functions of LAAO in MPN cell models
and provides additional insights into the development of new
therapies. However, it is still necessary to establish the spe-
ciﬁc effects of LAAO isolated from C. rhosostoma in normal
hematopoietic progenitors, primary cells from MPN patients
and JAK2V617F-driven murine models. The research con-
ducted by Tavares et al.15 also paves the way to an important
frontier of knowledge: even though JAK2V617F-positive cells
exhibit increased ROS levels compared to normal cells, the
overload of ROS can elicit apoptosis in JAK2V617F-positive
cells. The better understanding of the molecular mechanisms
involved in the survival of JAK2V617F-positive cells under
oxidative stress may be an interesting therapeutic opportu-
nity.
Based on the data presented by Tavares et al. in MPN
models and the ﬁndings from other research groups using
solid tumor models, and taking into account that JAK2/STAT5
activation leads to aberrant expressions of BCL-XL,22 future
investigations verifying the effects of the combined treatment
of JAK inhibitors and ROS inductors may be of interest.
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